BMO Capital analyst Sean Dodge initiated coverage of Privia Health (PRVA) with an Outperform rating and $30 price target The firm sees Privia as a “stable long-term earnings compounder with impressive” free cash flow. The stock offers one of the best ways to gain exposure to value-based care given the company’s highly recurring revenue and expansion opportunities, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $34 from $32 at Canaccord
- Privia Health price target raised to $23 from $22 at Barclays
- Privia Health’s Earnings Call Highlights Robust Growth
- Privia Health price target raised to $30 from $28 at Evercore ISI
- Privia Health price target raised to $31 from $30 at Citizens JMP